The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are ...

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

The FDA has declined to approve Columvi, in combination with the chemo regimen GemOx, for the treatment of second-line DLBCL ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

GSK plc GSK announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) has voted against the overall benefit/risk ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

The FTSE 100 index was up just 4.95 points at 8,977.59. The FTSE 250 gained 109.90 points, 0.5%, at 21,876.33, and the AIM All-Share climbed 2.54 points, 0.3%, at 771.47.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...